FDA Gives Priority Review to Depomed, Mallinckrodt Painkiller

NEW YORK (AP) -- Depomed Inc. and Mallinckrodt PLC said Monday that the Food and Drug Administration plans to conduct a faster review of their pain drug MNK-795.

The companies said the FDA will run a priority review of the drug, which means the agency expects to make a decision on their application in six months instead of the usual 10 months.

MNK-795 is a form of oxycodone and acetaminophen for moderate to severe acute pain. It includesDepomed's Acuform technology, which is designed to improve existing oral medications by allowing for their extended, controlled release to the upper gastrointestinal tract.

The FDA's acceptance of the application triggers a $5 million payment to Depomed by Mallinckrodt. Depomed said it will get another payment if MNK-795 is approved, and it will get royalty payments on sales.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2567200, ~/Articles/ArticleHandler.aspx, 9/30/2014 2:30:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement